Clinical trials: Cardiovascular Shock
Cardiogenic Shock
Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial
The primary objective of this study is to assess reasonable safety and performance of the HeartMate PHP to provide hemodynamic support for up to 72 hours in patients with cardiogenic shock requiring stabilization.
- Trial name
- NCT02279979
- Testing
- HeartMate PHP
- Where
- 6 sites in Czechia, Germany and 2 more
- Volunteers
- 9 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation (AF), Atrial Flutter
Head-to-Head (H2H) Comparison of Ambulatory Cardiac ECG Monitors in Japan
The goal of this clinical trial is to compare the yield of clinically actionable arrhythmias through the end of indicated wear duration in Zio monitor and Heartnote patch ECG devices.
- Conditions
- Atrial Fibrillation (AF), Atrial Flutter, Supraventricular Tachycardia (SVT), Ventricular Tachycardia (VT)
- Trial name
- Japan H2H (NCT07870837)
- Testing
- Application of ambulatory cardiac monitor
- Where
- 4 sites in Japan
- Volunteers
- 130 people
- Sponsor
- iRhythm Technologies, Inc.
Heart Diseases, Arrhythmia, Cardiac
Evaluation of the LVivo Image Quality Scoring (IQS)
The study includes two parts: Part 1: 100 examinations of patient referred for echo evaluation, containing clips that were acquired from the 4CH apical view were collected retrospectively.
- Conditions
- Heart Diseases, Arrhythmia, Cardiac, Angina Pectoris, Unstable Angina
- Trial name
- NCT05563701
- Where
- Israel
- Volunteers
- 164 people
- Sponsor
- DiA Imaging Analysis Ltd
AMI Cardiogenic Shock
Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
The observational study titled "Observational Assessment of Support with Impella Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock (OASIS-AMICS)" aims to evaluate the safety outcomes of patients with…
- Trial name
- OASIS-AMICS (NCT06964685)
- Testing
- Impella
- Where
- 21 sites in United States
- Volunteers
- 350 people
- Sponsor
- Abiomed Inc.
Tachyarrhythmia
ASSURE Study - Arrhythmia Single Shock DFT Versus ULV: Risk Reduction Evaluation With ICD Implantations
The ASSURE Study will evaluate shock conversion performance when programming the first shock of an implantable cardioverter-defibrillation (ICD) is based on an implant test consisting of either 1) a single induction of…
- Trial name
- NCT00231426
- Testing
- ICD
- Where
- United States
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
SONICURE（SONICracker for the Treatment of UndeRExpansion）
The first-phase study is a prospective, single-group observational study. It plans to recruit patients with in-stent restenosis caused by poor stent expansion in the coronary artery.
- Trial name
- NCT06924736
- Testing
- Intravascular Shockwave Therapy Device / Disposable Coronary Shockwave Catheter, Non - compliant balloon dilatation catheter
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
Cardiogenic Shock
Efficacy and Safety of the CorVad Percutaneous Ventricular Assist System in Cardiogenic Shock
This study aims to evaluate the safety and effectiveness of the CorVad Percutaneous Ventricular Assist System for providing circulatory support in patients with cardiogenic shock caused by cardiomyopathy.
- Trial name
- NCT06646224
- Testing
- CorVad Percutaneous Ventricular Assist System
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shenzhen Core Medical Technology CO.,LTD.
Shock, Cardiogenic
A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care.
The objective of this Phase 1b/2a trial is to evaluate the safety, tolerability, and exploratory efficacy of invobenitug (also known as procizumab), a monoclonal antibody under development for the treatment of cardiogenic shock…
- Trial name
- PROCARD 2a (NCT06832722)
- Testing
- AK1967 (Invobenitug also known as Procizumab)
- Where
- 37 sites in Armenia, Belgium and 7 more
- Volunteers
- 90 people
- Sponsor
- 4TEEN4 Pharmaceuticals GmbH